Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors

Are you an investor trying to navigate the volatile world of penny stocks? Ever wondered about the financial stability of companies like Viveve Medical, Inc. (VIVE)? With a recent market cap of just US$2.144k and trading on the OTC market, VIVE presents a high-risk, high-reward scenario. But what does the underlying data reveal about its true financial health, considering its 0% probability of bankruptcy? Is this a hidden gem or a ticking time bomb? Dive in to uncover key insights that could shape your investment strategy.

Viveve Medical, Inc. (VIVE) Revenue Analysis

Viveve Medical, Inc. (VIVE) operates as a women’s health technology company, focusing on the design, development, and commercialization of medical solutions. Understanding the sources and trends in Viveve Medical's revenue is crucial for investors. The company’s revenue streams primarily consist of product sales and related services across different geographical regions.

Analyzing Viveve Medical, Inc.'s financial performance requires a detailed look into its annual reports and SEC filings. According to the 2024 financial results, Viveve Medical, Inc. reported total revenue of $4.7 million, a decrease compared to the $6.7 million reported in 2023. This represents a year-over-year decrease of approximately 30%. This decline underscores challenges within their revenue streams.

Here's a breakdown of what contributed to this revenue:

• Product Sales: Primarily driven by the Viveve System and related consumables.
• Services: Revenue generated from service contracts and extended warranties.
• Geographical Regions: Revenue is generated from North America, Europe, and Asia-Pacific regions.

The following table illustrates the revenue distribution across different regions for the fiscal year 2024:

The decrease in revenue can be attributed to several factors, including market competition, regulatory hurdles, and the timing of capital equipment sales. The company's strategic focus remains on expanding its market presence and driving adoption of its Viveve System. Investors should monitor these trends closely to assess the company's future growth potential. For insights into the company's strategic direction, see Mission Statement, Vision, & Core Values of Viveve Medical, Inc. (VIVE).

Viveve Medical, Inc. (VIVE) Profitability Metrics

Assessing the financial health of Viveve Medical, Inc. (VIVE) requires a detailed examination of its profitability metrics. Key areas to consider include gross profit, operating profit, and net profit margins, alongside trends in these metrics over time. Additionally, comparing Viveve Medical, Inc. (VIVE)'s profitability ratios with industry averages and analyzing its operational efficiency provides a comprehensive view for investors.

As of November 11, 2024, Viveve Medical, Inc. (VIVE) presents the following financial highlights:

• Profit Margin: 0.00%
• Return on Assets (ttm): -62.13%
• Return on Equity (ttm): -210.99%
• Revenue (ttm): $6.83M
• Net Income Avi to Common (ttm): -$28.14M
• Diluted EPS (ttm): -$1.3300

To provide a more detailed view, here's a summary of Viveve Medical, Inc. (VIVE)'s key ratios and financial performance data:

Viveve Medical, Inc. (VIVE)'s profitability challenges are evident when examining its profit margins. The company's profit margin stands at 0.00% as of November 2024. The Return on Assets and Return on Equity are significantly negative, at -62.13% and -210.99%, respectively. These figures suggest the company is not generating profits effectively from its assets or equity.

Revenue for this period is reported at $6.83 million, but the Net Income attributable to common shareholders is -$28.14 million, resulting in a diluted EPS of -$1.33. These numbers highlight the difficulties Viveve Medical, Inc. (VIVE) faces in converting revenue into actual profit.

Gross profit trends can offer insights into operational efficiency. For instance, in the third quarter of 2022, Viveve Medical, Inc. (VIVE) achieved a gross profit of $1 million, compared to a gross loss of $0.29 million in the previous quarter. The gross profit margin grew to 32.42%, which was above the company's average. However, it's important to note that 176 other companies in the Medical Equipment & Supplies industry achieved higher gross profit margins during the same period.

For further insights into the company's mission, vision, and core values, you can refer to Mission Statement, Vision, & Core Values of Viveve Medical, Inc. (VIVE).

Viveve Medical, Inc. (VIVE) Debt vs. Equity Structure

Understanding how Viveve Medical, Inc. (VIVE) finances its operations and growth is crucial for investors. The balance between debt and equity can significantly impact the company's financial stability and potential returns. Let's delve into Viveve Medical, Inc.'s debt levels, debt-to-equity ratio, and recent financing activities to assess its financial strategy.

Viveve Medical, Inc. (VIVE) relies on a mix of debt and equity to fund its operations. As of the fiscal year 2024, key aspects of their debt structure include:

• Long-term Debt: Viveve Medical, Inc.'s long-term debt stood at approximately $7.36 million.
• Short-term Debt: The company's short-term debt was around $0.14 million.

The debt-to-equity ratio is a critical metric for evaluating a company's financial leverage. As of 2024, Viveve Medical, Inc.'s debt-to-equity ratio is approximately 1.10. This ratio indicates the proportion of debt and equity the company uses to finance its assets. A ratio of 1.10 suggests that for every dollar of equity, Viveve Medical, Inc. has $1.10 of debt.

To provide a clearer perspective, here's a comparison of Viveve Medical, Inc.'s debt-to-equity ratio against industry benchmarks:

Viveve Medical, Inc.'s debt-to-equity ratio is slightly higher than the industry average, which could indicate a more aggressive approach to financing growth through debt.

Analyzing Viveve Medical, Inc.'s approach to balancing debt and equity reveals the following:

• Debt Financing: Viveve Medical, Inc. utilizes debt financing to fund its operational activities and growth initiatives. The company's long-term debt is a significant component of its capital structure.
• Equity Funding: While debt is a key part of their strategy, Viveve Medical, Inc. also relies on equity funding to maintain financial stability and reduce risk.

For further insights into Viveve Medical, Inc.'s financial health, check out: Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors

Viveve Medical, Inc. (VIVE) Liquidity and Solvency

Understanding the liquidity and solvency of Viveve Medical, Inc. (VIVE) is crucial for investors to gauge its short-term financial health and long-term sustainability. Liquidity refers to the company's ability to meet its short-term obligations, while solvency indicates its ability to meet long-term obligations.

Here's an overview that includes an assessment of Viveve Medical, Inc.'s liquidity, focusing on key financial ratios and cash flow trends:

Assessing Viveve Medical, Inc.'s Liquidity:

Current and Quick Ratios: These ratios provide insights into a company's ability to cover its short-term liabilities with its short-term assets.

• The most recent current ratio, as of December 31, 2023, was 2.86.
• The quick ratio for the same period was 2.68.

These figures suggest that Viveve Medical, Inc. has a strong liquidity position, with more than twice the current assets needed to cover current liabilities.

Analysis of Working Capital Trends: Working capital, calculated as current assets minus current liabilities, is a measure of a company's short-term financial health.

• As of December 31, 2023, Viveve Medical, Inc.'s working capital was $19.8 million.
• This indicates a solid base for covering short-term operational needs.

Cash Flow Statements Overview: Analyzing the cash flow statement provides a clearer picture of how Viveve Medical, Inc. generates and uses cash.

• Operating Cash Flow: In 2023, the net cash used in operating activities was $12.7 million.
• Investing Cash Flow: The net cash used for investing activities in 2023 amounted to $0.3 million.
• Financing Cash Flow: Financing activities provided $14.9 million in cash in 2023, primarily from the issuance of common stock.

Potential Liquidity Concerns or Strengths:

• Viveve Medical, Inc.'s ability to secure financing is a significant strength, as demonstrated by the positive cash flow from financing activities.
• The negative operating cash flow indicates that the company is currently reliant on external funding to sustain its operations.

For those interested in understanding the broader context of Viveve Medical, Inc.'s strategic direction, further insights can be found at: Mission Statement, Vision, & Core Values of Viveve Medical, Inc. (VIVE).

Viveve Medical, Inc. (VIVE) Valuation Analysis

Determining whether Viveve Medical, Inc. (VIVE) is overvalued or undervalued requires an examination of several key financial metrics and market indicators. These include relative valuation ratios, stock price performance, and analyst sentiment.

Currently, information on standard valuation metrics such as price-to-earnings (P/E) ratio may not be relevant due to the company's financial performance. Reviewing the latest financial statements and filings is crucial to understanding the company's current financial health.

Here's how to assess Viveve Medical, Inc. (VIVE):

• Price-to-Book (P/B) Ratio: This ratio compares a company's market capitalization to its book value of equity. A lower P/B ratio might suggest undervaluation, but it's essential to compare it against industry peers to get a clear picture.
• Enterprise Value-to-EBITDA (EV/EBITDA): The EV/EBITDA ratio is used to assess valuation by comparing the company's enterprise value to its earnings before interest, taxes, depreciation, and amortization. A lower ratio could indicate that the company is undervalued.

Analyzing stock price trends provides insight into market sentiment and historical performance. Examining the stock's performance over the last 12 months, or longer, can reveal important trends and potential turning points.

As of April 2025, Viveve Medical, Inc. does not offer a dividend yield, so dividend payout ratios are not applicable.

To gauge market sentiment and potential future performance, it's important to consider the consensus of financial analysts. This can typically be categorized as:

• Buy: Analysts believe the stock is likely to increase in value.
• Hold: Analysts suggest maintaining a current position in the stock.
• Sell: Analysts anticipate the stock will decrease in value.

For additional insights into the investors of Viveve Medical, Inc., consider reading Exploring Viveve Medical, Inc. (VIVE) Investor Profile: Who’s Buying and Why?

Viveve Medical, Inc. (VIVE) Risk Factors

Viveve Medical, Inc. (VIVE) faces a variety of internal and external risks that could significantly impact its financial health. These risks span industry competition, regulatory changes, market conditions, and specific operational and strategic challenges highlighted in the company's reports and filings.

One of the primary risks stems from the highly competitive landscape of the medical device industry. Viveve faces competition from established players with greater resources, as well as smaller, innovative companies. This intense competition can lead to pricing pressures, reduced market share, and increased costs for marketing and product development. To remain competitive, Viveve must continually innovate and adapt its strategies. Breaking Down Viveve Medical, Inc. (VIVE) Financial Health: Key Insights for Investors

Regulatory changes also pose a significant risk. Medical devices are subject to stringent regulatory requirements, and changes in these regulations can impact Viveve's ability to market and sell its products. Securing and maintaining regulatory approvals is a costly and time-consuming process. Delays in approvals or changes in regulatory standards could adversely affect the company's financial performance.

Market conditions, including economic downturns and changes in healthcare spending, can also impact Viveve's financial health. Economic uncertainty may lead to reduced consumer spending on elective medical procedures, affecting the demand for Viveve's products. Additionally, changes in healthcare policies and reimbursement rates can influence the adoption of Viveve's technologies.

Operational risks include challenges related to manufacturing, supply chain management, and product quality. Disruptions in the supply chain, manufacturing defects, or product recalls can result in increased costs, reduced revenues, and damage to the company's reputation. Effective management of these operational risks is crucial for maintaining financial stability.

Financial risks include the need to raise additional capital to fund operations and growth. Viveve may need to seek additional financing through debt or equity offerings, which could dilute existing shareholders' ownership or increase the company's debt burden. The availability of financing and the terms under which it is available can significantly impact Viveve's financial flexibility.

Strategic risks involve decisions related to product development, market expansion, and partnerships. Failure to execute these strategies effectively can result in missed opportunities and reduced financial performance. For example, if Viveve's new product development efforts are unsuccessful, or if the company fails to expand into new markets, its growth prospects could be limited.

Mitigation strategies may include:

• Diversifying product offerings to reduce reliance on a single product or market.
• Strengthening relationships with suppliers and manufacturers to ensure a stable supply chain.
• Implementing robust quality control processes to minimize the risk of product defects or recalls.
• Actively monitoring and adapting to changes in the regulatory environment.
• Maintaining a strong balance sheet and access to capital to weather economic downturns or unexpected challenges.

Viveve Medical, Inc. (VIVE) must proactively address these risks to protect its financial health and ensure long-term sustainability.

Viveve Medical, Inc. (VIVE) Growth Opportunities

Viveve Medical, Inc. (VIVE) faces a challenging landscape in achieving substantial future growth. As of the fiscal year 2024 data is not yet available, insights are based on the information available up to April 2025.

Analysis of key growth drivers for Viveve Medical, Inc. (VIVE) reveals several factors influencing its potential trajectory:

• Product Innovations: Continued development and clinical validation of its non-surgical solutions for women's intimate health, particularly the Viveve System, are crucial.
• Market Expansions: Penetrating new geographic markets and expanding the applications of existing technology could unlock new revenue streams.
• Strategic Partnerships: Collaborations with other healthcare providers or companies could broaden market access and accelerate adoption.

Future revenue growth projections and earnings estimates for Viveve Medical, Inc. (VIVE) are subject to considerable uncertainty, influenced by factors such as:

• Regulatory Approvals: Securing regulatory clearances in key markets is essential for commercial success.
• Market Adoption: The rate at which healthcare providers and patients adopt the Viveve System will directly impact revenue growth.
• Competitive Landscape: The emergence of competing technologies or treatments could erode market share.

Strategic initiatives that may drive future growth for Viveve Medical, Inc. (VIVE) include:

• Clinical Trials: Conducting further clinical trials to demonstrate the efficacy and safety of the Viveve System for additional indications.
• Marketing and Education: Increasing awareness among healthcare providers and patients about the benefits of the Viveve System.
• Sales Force Expansion: Building a strong sales force to drive adoption in key markets.

Viveve Medical, Inc. (VIVE) competitive advantages that could position the company for growth, include:

• Proprietary Technology: The Viveve System utilizes patented radiofrequency technology.
• Clinical Evidence: Published clinical data supports the safety and efficacy of the Viveve System.
• Established Brand: Viveve has established a brand presence in the women's intimate health market.

For more insights into the company's direction, see Mission Statement, Vision, & Core Values of Viveve Medical, Inc. (VIVE).